EP4196116
PHARMACEUTICAL COMPOSITION COMPRISING CABOZANTINIB, PLERIXAFOR, AFATINIB AND ETORICOXIB FOR USE IN THE TREATMENT OR PROPHYLAXIS OF NSCLC WITHOUT DRIVER MUTATIONS
:
EP einkaleyfi: Þýðing ekki lögð inn:
12.8.2021:
10.7.2024:
21766393.9
:
11.8.2041
:
PHARMACEUTICAL COMPOSITION COMPRISING CABOZANTINIB, PLERIXAFOR, AFATINIB AND ETORICOXIB FOR USE IN THE TREATMENT OR PROPHYLAXIS OF NSCLC WITHOUT DRIVER MUTATIONS
12.8.2021
10.7.2024
:
Langhammer, Stefan:
Hirschweg 8, 30938 Burgwedel, DE
:
EPO Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH:
Robert-Rössle-Str. 10 Haus 82, 13125 Berlin, DE
:
HOFFMANN, Jens:
13125 Berlin, DE
:
GÜRGEN, Dennis:
13409 Berlin, DE
:
LANGHAMMER, STEFAN, Dr.:
30938 Burgwedel, DE
:
102020005002:
17.8.2020:
DE
:
EP2021072486:
12.8.2021
:
A61K 31/395, A61K 31/444, A61K 31/47, A61K 31/517, A61K 45/06, A61P 35/00